Public Profile

Emmaus Life Sciences, Inc.

Emmaus Life Sciences, Inc., a leading biopharmaceutical company headquartered in the United States, is dedicated to developing innovative therapies for rare diseases. Founded in 2002, the company has made significant strides in the industry, particularly in the treatment of sickle cell disease. Emmaus is renowned for its flagship product, Endari, which is the first FDA-approved treatment specifically for patients aged five and older with this condition. The unique formulation of L-glutamine in Endari helps reduce the frequency of painful crises and hospitalisations, setting it apart in the market. With a strong commitment to research and development, Emmaus Life Sciences continues to expand its operational reach, aiming to improve the quality of life for patients globally. The company’s dedication to addressing unmet medical needs positions it as a notable player in the biopharmaceutical landscape.

DitchCarbon Score

How does Emmaus Life Sciences, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

23

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Emmaus Life Sciences, Inc.'s score of 23 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.

0%

Let us know if this data was useful to you

Emmaus Life Sciences, Inc.'s reported carbon emissions

Emmaus Life Sciences, Inc., headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year, nor does it specify any reduction targets or initiatives. Without specific emissions figures or commitments, it is unclear how the company is addressing its carbon footprint or contributing to climate action. In the absence of detailed information, it is essential to monitor their future disclosures for any developments regarding their climate commitments and sustainability practices.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Emmaus Life Sciences, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Emmaus Life Sciences, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Emmaus Life Sciences, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

CRISPR Therapeutics AG

CH
Health and social work services (85)
Updated 1 day ago

Novartis International AG

CH
Real estate services (70)
Updated 3 months ago
DitchCarbon Score

Geron Corporation

US
Health and social work services (85)
Updated 1 day ago

Novartis Pharmaceuticals Corporation

US
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

American Well Corporation

US
Computer and related services (72)
Updated 1 day ago

PharmaEssentia USA Corporation

US
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers